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BACKGROUND: Pancreatic cancer cells are highly resistant to drug therapy; however, underlying causes remain largely unknown. We
hypothesised that the activation of CXCL12–CXCR4 signalling confers drug resistance to pancreatic cancer cells by potentiating
survival. CXCR4 is overexpressed in precancerous/malignant pancreatic lesions and cancer stem cells, and implicated in its
pathogenesis.
METHODS: Effect of CXCR4 activation by CXCL12 on restricting the gemcitabine-induced cytotoxicity and stimulating the survival
signalling was examined in pancreatic cancer cells by MTT, DNA laddering, caspase activity, immunoblot, and promoter-reporter
assays. Subsequently, we examined the effect of CXCR4 antagonist, AMD3100, in abrogating the rescue effect of activated
CXCL12–CXCR4 signalling.
RESULTS: The pancreatic cancer cells treated with gemcitabine exhibited reduced cytotoxicity in the presence of CXCL12 as
compared with the cells treated with drug alone. CXCL12 induced the activation of FAK, ERK, and Akt signalling pathways, enhanced
transcriptional activities of b-catenin and NF-kB, and expression of survival proteins. AMD3100 arrested the CXCL12-induced
pancreatic cancer cell growth and drug resistance.
CONCLUSION: Our findings demonstrate, for the first time, a role of CXCL12–CXCR4 signalling axis in conferring drug resistance to
pancreatic cancer cells and suggest that it could serve as a novel therapeutic target for pancreatic cancer therapy, alone and in
combination with the cytotoxic drug.
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Pancreatic cancer is a highly lethal malignancy with an extremely
poor prognosis. The overall median survival after diagnosis is 2–8
months, and only 1–4% of all patients with pancreatic adeno-
carcinoma survive 5 years after diagnosis (Singh et al, 2004).
According to an estimate of the American Cancer Society, 42470
Americans were diagnosed with pancreatic cancer in 2009 and
35240 died from it, marking this malignancy as the fourth leading
cause of cancer deaths (Jemal et al, 2009). Surgical resection is the
best and most effective choice for treatment, but in majority of the
cases, the disease is locally advanced or has already metastasised to
distant organs at the time of diagnosis. In the latter scenario,
chemotherapy is considered as an option, but the effects are
usually modest due to chemoresistance (Liau and Whang, 2008;
Rejiba et al, 2009). Drug resistance in pancreatic cancer cells is
thought to occur mainly as a result of active survival mechanisms
and/or inefficient drug delivery because of the fibrotic nature of
pancreatic tumours (Olive et al, 2009; Pei et al, 2009). Hence, there
is an urgent need to develop alternative strategies and novel
therapeutics for effective treatments of this devastating malignancy
and improve clinical outcome.
The chemokine receptor, CXCR4, is expressed in a variety of
malignancies and has been extensively studied for its role in cancer
pathogenesis (Singh et al, 2007; Gelmini et al, 2008). CXCR4
expression is elevated in majority of pancreatic cancer tissues and
precancerous lesions, suggesting its role in pancreatic cancer
pathogenesis (Thomas et al, 2008; Marechal et al, 2009). CXCL12, a
ligand for CXCR4, is also abundantly produced by neighbouring
stromal cells and activation of CXCR4-expressing pancreatic
cancer cells by CXCL12 leads to enhanced chemotaxis, transen-
dothelial migration, and Matrigel invasion (Marchesi et al, 2004;
Matsuo et al, 2009). Furthermore, high concentrations of CXCL12
are present at the common sites of pancreatic metastases (lymph
nodes, liver, lungs, and so on), suggesting that CXCL12–CXCR4
signalling may have a role in the homing of pancreatic cancer cells
to specific organs (Mori et al, 2004; Saur et al, 2005). Importantly,
a recent study also showed that a distinct subpopulation of
CD133
þ;CXCR4
þ cancer stem cells (CSCs) was present at the
leading edge of invasive pancreatic tumours, indicating a potential
role of CXCR4 in the invasion process (Hermann et al, 2007).
CXCR4 expressed on pancreatic CSCs was shown to be essential
for their invasive and metastatic properties, suggesting a strong
correlation with disease aggression (Hermann et al, 2007). The
CXCL12–CXCR4 signalling axis has also been implicated in
desmoplastic alterations of surrounding stroma favoring tumour
cell growth (Marlow et al, 2008). In other studies, CXCL12–CXCR4
signalling was shown to stimulate pancreatic cancer cell proliferation
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sand protection of cancer cells from serum deprivation-induced
apoptosis (Koshiba et al, 2000; Marchesi et al, 2004; Saur et al,
2005; Marlow et al, 2008). Altogether, these observations indicate
an important role of CXCR4 signalling in pancreatic cancer
survival, proliferation, invasion, and metastasis, suggesting this
signalling axis as a potential target for cancer therapy.
Gemcitabine is the only FDA-approved chemotherapeutic drug
for the treatment of advanced and metastatic pancreatic cancer.
However, it has not proven very effective clinically, and improve-
ment in patient’s survival undergoing gemcitabine therapy is
only minimal (Olive et al, 2009; Wong and Lemoine, 2009). In this
study, we hypothesised that the CXCL12–CXCR4 signalling axis is
involved in pancreatic cancer drug resistance by stimulating
intrinsic cell survival mechanisms. We have investigated the effect
of CXCL12 in restricting the gemcitabine-induced toxicity of
pancreatic cancer cells and activation of survival signalling
pathways. Furthermore, we examined the therapeutic significance
of a CXCR4 antagonist, AMD3100, in preventing the rescue effect of
activated CXCL12–CXCR4 signalling. Our data demonstrate that
CXCL12 induces a series of signalling events in pancreatic cancer
cells and counteracts the cytotoxic effects of gemcitabine.
In addition, our data show that AMD3100 can abrogate the survival
effect of CXCL12–CXCR4 signalling and can serve as a therapeutic
modality either alone or in combination with gemcitabine to
effectively inhibit the growth of pancreatic cancer cells.
MATERIALS AND METHODS
Cell lines and culture conditions
Human pancreatic cancer cell lines (Colo357, SW1990, AsPc1,
BxPc3, CaPan1, HPAF II, CFPAC1, Panc1, MiaPaCa, Panc10. 05,
Panc03.27, Panc02.03) were purchased from the American Type
Culture Collection (Manassas, VA, USA). The cell lines were
maintained in culture as adherent monolayer in RPMI-1640 or
Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Scientific,
Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS)
(Atlanta Biologicals, Lawrenceville, GA, USA) and 100mM each of
penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA). Cells
were grown at 371C with 5% CO2 in humidified atmosphere.
Reagents
SuperScript II Reverse Transcriptase and Vybrant MTT cell
proliferation assay kit were from Invitrogen. Recombinant human
CXCL12 and CXCL12 ELISA kit were purchased from R&D
Systems (Minneapolis, MN, USA). AMD3100 octahydrochloride
and anti-b-actin mouse monoclonal antibody were purchased from
Sigma-Aldrich (St Louis, MO, USA). Gemcitabine was provided by
USAMCI pharmacy. Phosphatase and protease inhibitors and
FuGENE transfection reagent were from Roche Diagnostics
(Mannheim, Germany). Antibody against CXCR4 (rabbit poly-
clonal) was from Abcam (Cambridge, MA, USA). Anti-Akt, -pAkt,
and -pFAK (rabbit monoclonal) antibodies were from Epitomics
(Burlingame, CA, USA). Antibodies for ERK1/2 (rabbit mono-
clonal), pERK1/2 (mouse monoclonal), Bcl-2 (rabbit polyclonal),
BAD (rabbit monoclonal), pBAD (rabbit polyclonal), Bcl-xL
(rabbit monoclonal), focal adhesion kinase (FAK) (rabbit poly-
clonal), and Survivin (rabbit monoclonal) were from Cell Signaling
Technologies (Beverly, MA, USA). The Notch1 (goat polyclonal)
and secondary horseradish peroxidase-conjugated anti-rabbit,
anti-mouse, and anti-goat antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). DNAzol reagent was
from Molecular Research (Cincinnati, OH, USA). CaspACE
FITC-VAD-FMK and Dual Luciferase Assay System kit were from
Promega (Madison, WI, USA). ECL Plus Western Blotting
detection kit, DharmaFECT transfection reagent, ON-TARGET
plus non-targeting pool scrambled siRNAs and SMARTpool
siRNAs targeting CXCR4 were from Thermo Scientific. LY294002
and PD98059 (PI3K and MEK1 inhibitors, respectively) were
purchased from Cell Signaling Technology. TOPflash or FOPflash
reporter plasmids were kindly provided by Dr R Samant,
USAMCI, and pGL4.32[luc2P/NF-kB-RE/Hygro] reporter plasmid
was purchased from Promega.
Western blot analysis
Cells were processed for protein extraction and western blotting
using standard procedures. Briefly, the cells were washed twice
with phosphate-buffer saline (PBS) and scraped into NP-40 lysis
buffer containing protease and phosphotase inhibitors. Cell lysates
were passed through a needle syringe to facilitate the disruption
of the cell membranes and were centrifuged at 14000r.p.m.
for 20min at 41C, and supernatants were collected. Proteins
(10–50mg) were resolved by electrophoresis on 10% SDS–PAGE,
transferred onto polyvinylidene difluoride membrane and sub-
jected to standard immunodetection procedure using specific
antibodies: Akt, pAkt ERK1/2 pERK1/2, Bcl-2, Bcl-xL, FAK, pFAK,
Survivin, b-catenin and BAD (1:1000), pBAD (1:500), Notch-1
(1:200), and b-actin (1:20000). All secondary antibodies were
used at 1:2500 dilutions. Blots were processed with ECL Plus
Western Blotting detection kit and the signal detected using an
LAS-3000 image analyzer (Fuji Photo Film Co., Tokyo, Japan).
Enzyme-linked immunosorbent assay
Cells (1 10
6) were seeded in six-well plates containing growth
medium supplemented with FBS and cultured overnight. After
24h, growth media were removed, and cells were conditioned in
serum-free medium for next 72h. The culture media were then
collected, centrifuged at 1500r.p.m. for 5min to remove particles,
and supernatants frozen at  801C until use. CXCL12 was measured
using an ELISA kit according to the manufacturer’s instructions.
LEF/TCF and NF-jB transcriptional activity assays
To measure the LEF/TCF and NF-kB transcriptional activity,
pancreatic cancer cells (1 10
5) were seeded in 12-well plates.
After 24h incubation, cells were transiently transfected with the
luciferase promoter-reporter constructs (TOPflash, FOPflash, or
pGL4.32[luc2P/NF-kB-RE/Hygro]). TOPflash reporter plasmid
contains three copies of the Tcf/Lef sites upstream of a thymidine
kinase (TK) promoter and the Firefly luciferase gene, whereas in
FOPflash, Tcf/Lef sites are mutated and therefore it serves as a
control for measuring nonspecific activation of the reporter. Cells
were also co-transfected with a reporter plasmid, containing
Renilla reniformis luciferase gene downstream of the TK promoter,
to control for the transfection efficiency. All transfections were
performed using FuGENE as a transfection reagent according to the
manufacturers’ recommendations. Cells were treated with CXCL12
(100ngml
 1) 24h post-TOPflash/FOPflash or pGL4.32[luc2P/NF-
kB-RE/Hygro] transfection, and after the next 24h, total protein was
isolated in passive lysis buffer. Luciferase activity was measured
using the Dual Luciferase Assay System. All experiments were
carried out in triplicate and relative luciferase activity reported as
the fold induction after normalisation for transfection efficiency.
Cell viability assay
Panc1 and MiaPaCa cells were seeded in 96-well plates at a density
of 5000 cells per well, followed by next day treatment with
increasing concentration of gemcitabine (0–10mM) in the presence
or absence of CXCL12 (100ngml
 1). After 72h of treatment, cell
growth was determined by using Vybrant MTT cell proliferation
assay. Growth was calculated as percent (%)¼[((A/B) 1) 100],
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Figure 1 CXCR4 and CXCL12 expression and growth response in pancreatic cancer cells. (A) Total protein was isolated from 12 pancreatic cancer cell
lines and resolved on 10% SDS–polyacrylamide gels by electrophoresis. Subsequently, the gels were immunoblotted with anti-CXCR4 rabbit polyclonal
antibodies and reprobed with anti-b-actin (internal control) mouse monoclonal antibody. CXCR4 was expressed (at varying levels) in all pancreatic
cancer cell lines tested. (B) Enzyme-linked immunosorbant assay (ELISA) was performed on used culture media from pancreatic cancer cells grown under
serum-free condition for 72h using a commercial kit. Low level CXCL12 expression (13–230pg per ml per 10
6 cells) was detected in all pancreatic cancer
cell lines. (C) Growth response of pancreatic cancer cells (MiaPaCa and Panc1) on CXCL12 treatment (100ngml
 1) indicating the functionality of
CXCL12–CXCR4 signalling axis. CXCL12 stimulation (in serum-deprived and -supplemented media) led to the significant induction (*Po0.01) of growth in
pancreatic cancer cells. Responses were more pronounced under serum-free conditions than in serum-containing cultures likely due to the compensatory
growth-promoting effects of other serum factors.
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Figure 2 Rescue of pancreatic cancer cells from gemcitabine-induced toxicity on CXCL12 treatment. Two pancreatic cancer cell lines, Panc1 (A) and
MiaPaCa (B), were treated with various doses of gemcitabine (0–10mM) under serum-supplemented condition in the presence and absence of CXCL12
(100ngml
 1). Cancer cell viability was examined 72h post-treatment by MTT assay. Significant protection of pancreatic cancer cells from gemcitabine
toxicity (at 5 and 10mM) by CXCL12 was observed. Data are presented as relative survival with respect to untreated or CXCL12 only-treated cells to
control for the growth-promoting effect of CXCL12 (*Po0.01).
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swhere A and B are the absorbance of treatment and control cells,
respectively. To examine the effect of CXCR4 targeting, cells were
preincubated with small-molecule CXCR4 antagonist, AMD3100
(5mgml
 1), for 1h. To delineate the role of Akt and ERK path-
ways, cells were pretreated for 1h with LY294002 (20mM) and
PD98059 (25mM), respectively. To further corroborate the role of
CXCR4, Panc1 and MiaPaCa cells were also transiently transfected
with CXCR4- or non-targeted siRNA pools using DharmaFECT
transfection reagent (Thermo Scientific) as per the manufacturer’s
protocol. After 24h, cells were treated with gemcitabine (5mM) and
cells viability was examined 72h post-treatment.
DNA fragmentation assay
Panc1 and MiaPaCa cells were cultured in 10% DMEM with and
without gemcitabine (5 and 10mM) and CXCL12 (100ngml
 1) for
48h. Cells were washed twice with PBS and DNA (2 mg) was
extracted using DNAzol reagent. Isolated DNA was resolved on
1.0% agarose gel containing ethidium bromide (EtBr) and
observed under a LAS-3000 image analyzer (Fuji Photo Film Co.).
Measurement of apoptosis in situ
Panc1 and MiaPaCa cells were cultured on chamber slides and
treated with gemcitabine and/or CXCL12 as described previously.
Apoptosis was detected by staining the cells with CaspACE
FITC-VAD-FMK solution in PBS for 2h at 371C. CaspACE FITC-
VAD-FMK In Situ Marker is a fluorescent analogue of the
pancaspase inhibitor Z-VAD-FMK (carbobenzoxy-valyl-alanyl-
aspartyl-[O-methyl]-fluoromethylketone), which irreversibly binds
to activated caspases and is a surrogate for caspase activity in situ.
Following staining with CaspACE FITC-VAD-FMK, cells were fixed
with 4% paraformaldehyde at room temperature and washed with
PBS. The bound fluorescent marker was detected under a Nikon
Eclipse TE2000-U fluorescent microscope (Nikon Instruments Inc.,
Melville, NY, USA).
Statistical analysis
Each experiment was performed at least three times, and all the
values were expressed as mean±s.d. The differences between the
groups were compared using student’s t-tests. A P-value of p0.05
was considered statistically significant.
RESULTS
Expression of CXCR4 and CXCL12 in pancreatic cancer
cells and their growth responsiveness to CXCL12
stimulation
Earlier it has been shown that CXCR4 is overexpressed in
pancreatic tumour tissues and premalignant lesions (Thomas
et al, 2008; Marechal et al, 2009). In addition, CXCR4 is also
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Figure 3 Antiapoptotic effects of CXCL12 treatment on gemcitabine-induced cell death. (A) DNA fragmentation assay. Cells were seeded in 6-cm Petri
dishes and treated with 5 and 10mM gemcitabine in the absence or presence of CXCL12 (100ngml
 1) for 48h. Subsequently, genomic DNA was isolated
and resolved (2mg per lane) on 1% agarose gel. Lane 1: untreated, lanes 2 and 3: gemcitabine-treated (5 and 10mM), respectively, and lanes 4 and 5:
gemcitabine-treated (5 and 10mM, respectively) in the presence of CXCL12. CXCL12-treated pancreatic cancer cells exhibit reduced DNA laddering
compared with cells treated with gemcitabine only. (B) In situ determination of apoptosis. Panc1 and MiaPaCa cells were cultured on chamber slides and
treated with gemcitabine (5mM) in the absence and presence of CXCL12 (100ngml
-1). Apoptosis was detected by staining the cells with CaspACE
FITC-VAD-FMK solution in PBS for 2h at 371C. Following fixation, bound marker was visualised by fluorescent detection under a confocal microscope.
Representative pictures (overlay of FITC and DAPI) are from one of the random fields of untreated, gemcitabine only, and gemcitabineþCXCL12-treated
Panc1 and MiaPaCa cells. Apoptotic cells that stained positively with FITC-labelled marker were counted in 10 random fields and presented in a bar diagram
(mean±s.d.). *Significant difference as compared with gemcitabine only-treated cells. CXCL12 co-treated cells exhibited 53 and 55% reduced apoptosis by
gemcitabine in Panc1 and MiaPaCa cells, respectively.
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sexpressed by the pancreatic CSCs (Hermann et al, 2007). Here, we
examined the expression of CXCR4 and its ligand CXCL12 by
immunoblot and enzyme-linked immunosorbant assay (ELISA),
respectively, in a panel of 12 pancreatic cancer cell lines. Our
data show that all pancreatic cancer cell lines examined express
CXCR4 and low levels of CXCL12 (13–230pg per ml per 10
6 cells)
(Figure 1A and B). We further tested the growth responsiveness
of pancreatic cancer cells to CXCL12 stimulation in two poorly
differentiated pancreatic cancer cell lines, MiaPaCa and Panc1. The
cells were treated with CXCL12 in serum-free and serum-contain-
ing culture media. In the absence of serum growth factors, CXCL12
stimulation led to the 29–33% induction of growth in pancreatic
cancer cells, whereas a moderate increase (11–13%) was observed
in the presence of serum growth factors (Figure 1C). These
findings suggest that CXCL12–CXCR4 signalling is active in
pancreatic cancer cells and can impact tumour cell growth.
CXCR4 activation rescues pancreatic cancer cells from
gemcitabine-induced cytotoxicity
Although our data indicated minimal expression of CXCL12 by
pancreatic cancer cells (Figure 1B), it is reported to be expressed at
high levels by stromal cells and at sites of pancreatic cancer
metastasis (Mori et al, 2004; Saur et al, 2005; Matsuo et al, 2009).
Therefore, CXCL12–CXCR4 signalling might act in paracrine
manner to influence pancreatic tumour growth and other
malignant properties. In view of the fact that pancreatic cancer
cells are highly resistant to chemotherapy, and gemcitabine (an
FDA-approved drug) is only minimally effective against this
malignancy, we investigated the role of CXCL12–CXCR4 signalling
axis in pancreatic cancer chemoresistance. We treated pancreatic
cancer cells (Panc1 and MiaPaCa) with various doses of
gemcitabine (0–10mM) in the presence and absence of CXCL12
(100ngml
 1) in serum-containing media. Our data show that
CXCL12 treatment induced significant resistance (Po0.01) to
gemcitabine cytotoxicity in both pancreatic cancer cell lines tested
(Figure 2A and B). At 5.0mM dose of gemcitabine, we observed 52.3
and 50.7% cytotoxicity in Panc1 and MiaPaCa cells, respectively, as
compared with untreated cells. In contrast, only 27.1 and 20.5%
gemcitabine cytotoxicity, respectively, was reported in cells co-
treated with CXCL12, indicating a significant survival advantage.
To substantiate the role of CXCR4 in CXCL12-induced chemopre-
ventive effect, Panc1 and MiaPaCa cells were transiently trans-
fected with CXCR4- or non-targeted siRNA pools 24h before
gemcitabine treatment in the presence and absence of CXCL12.
Resulting cell viability data show that CXCL12-induced cytopro-
tective effect is abolished when the cells are silenced for CXCR4
expression (Supplementary Figure S1). Next, we examined whether
CXCL12-induced chemoresistance was due to its antiapoptotic
effects on pancreatic cancer cells, DNA fragmentation and
decreased caspase. Our data demonstrate that CXCL12-treated
cells have reduced DNA fragmentation (Figure 3A) and decreased
activity of caspases (Figure 3B) compared with cells treated with
gemcitabine alone. These findings strongly suggest that CXCL12
treatment prevents apoptosis of pancreatic cancer cells by
gemcitabine and suggest the implication of CXCL12-elicited
survival pathways.
CXCL12 treatment leads to FAK, Akt, and ERK activation
In next set of experiments, we examined the potential survival
signalling pathways that might mediate the CXCL12-elicited
chemoresistance. Because G-protein-coupled receptors transduce
signals through diverse signalling pathways, including activation
of FAK, PI3K/Akt, and ERK (Rozengurt, 2007), we investigated the
activation of these signalling molecules in response to CXCL12
treatment. Pancreatic cancer cells (Panc1 and MiaPaCa) were
briefly treated with CXCL12 (5–30min), and activation of FAK,
Akt, and ERK was examined by immunoprobing of total protein
with phospho-form-specific antibodies. Our data revealed sig-
nificant activation of all the three effector proteins in response to
CXCL12 treatment (Figure 4). Both Akt and ERK have been shown
to promote survival by phosphorylating BAD (a proapoptotic
member of the Bcl-2 family) and thereby controlling its association
with Bcl-xL or Bcl-2 (antiapoptotic members of the family)
(Datta et al, 1997; Scheid and Duronio, 1998; Sheridan et al,
2008). Therefore, we examined the change in BAD phosphorylation
in CXCL12-treated pancreatic cancer cells. Our data showed an
increased level of phospho-BAD in both Panc1 and MiaPaCa cell
lines treated with CXCL12 (Figure 4), suggesting that it could be
one of the mechanisms by which CXCL12–CXCR4 signalling axis
protects the pancreatic cancer cells from apoptosis.
Enhanced transcriptional activities of b-catenin and NF-jB
and induction of survival proteins by CXCL12 treatment of
pancreatic cancer cells
In addition to directly influencing apoptotic signalling by BAD
phosphorylation, both Akt and ERK can have indirect impacts on
cell survival. The indirect routes involve the activation of b-catenin
and NF-kB that can elicit the expression of survival proteins.
Therefore, we examined the transcriptional activities of b-catenin
and NF-kB responsive promoters after CXCL12 treatment in
pancreatic cancer cells. Luciferase reporter assays indicated
modest induction of transcriptional activity of b-catenin (2.05-
fold (Panc1) and 1.92-fold (MiaPaCa)) and NF-kB responsive
promoter (2.98-fold (Panc1) and 2.26-fold (MiaPaCa)) in CXCL12-
treated cells (Figure 5A). As activation of b-catenin and NF-kB
may culminate in the induction of important survival genes, we
CXCL12 treatment CXCL12 treatment
0 5 15 30 0 5 15 30 (min)
pBAD
BAD
pFAK
FAK
pERK1/2
ERK1/2
pAkt
Akt
-Actin
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Figure 4 CXCL12-induced activation of FAK, Akt, and ERK pathways.
Sub-confluent Panc1 and MiaPaCa cell cultures were treated with CXCL12
(100ngml
 1) for 5, 15, and 30min durations. Protein was extracted and
resolved on SDS–polyacrylamide gels by electrophoresis. Activation of
FAK, Akt, and ERK pathways was assessed by immunoblotting using total
and phospho-form-specific antibodies as indicated. b-Actin served as an
internal control. CXCL12 treatment induced the phosphorylation of all
three effector proteins with a concomitant inactivating phosphorylation of
proapoptotic BAD protein in both Panc 1 and MiaPaCa cell lines.
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sexamined the expression of target prosurvival and antiapop-
totic proteins. Our data showed that the expression of Bcl-2,
Bcl-xL, Notch-1, and survivin proteins was significantly induced
in response to CXCL12 treatment of pancreatic cancer cells
(Figure 5B). These results suggest that the upregulation of
key survival proteins may be another mechanism by which
CXCL12–CXCR4 signalling axis protects the pancreatic cancer
cells from gemcitabine-induced apoptotic cell death.
Small-molecule CXCR4 antagonist, AMD3100, abrogates
CXCL12-induced growth and gemcitabine resistance in
pancreatic cancer cells
Having observed a role of CXCR4 activation in gemcitabine
resistance and potentiation of survival pathways, we investigated
if the small-molecule CXCR4 antagonist, AMD3100, could
diminish CXCL12-induced chemoresistance in pancreatic cancer
cells. In addition, we also utilised pharmacological inhibitors of
Akt (LY294002) and ERK (PD98059) signalling pathways, to
delineate their role in the CXCL12-induced antiapoptotic response.
Pancreatic cancer cells were treated for 1h with AMD3100,
LY294002, and PD98059 before treatment with CXCL12 alone or
in combination with gemcitabine. Pretreatment with AMD3100
abolished the CXCL12-induced cell signalling, growth promotion,
and chemoresistance of pancreatic cancer cells (Figure 6A and B).
Although both the inhibition of Akt and ERK pathways had a
significant negative impact on CXCL12-induced chemoresistance,
a more potent effect of blockade of Akt signalling was observed
(Figure 6B). These findings indicate that CXCL12-mediated
survival response is signalled through the CXCR4 and mediated
through the activation of Akt and ERK signalling pathways. This
is particularly important considering the expression of a novel
CXCL12 receptor, CXCR7, in pancreatic cancer cells at least at the
transcript level (data not shown).
DISCUSSION
Pancreatic cancer, in most cases, is diagnosed late, when it has
already advanced locally or metastasised to distant sites (Singh
et al, 2004). Under this scenario, chemotherapy is the only
treatment option. However, resistance to chemotherapy is a major
clinical problem in pancreatic cancer and gemcitabine, the only
FDA-approved drug for pancreatic cancer therapy improves the
patients’ survival by only 2 weeks (Olive et al, 2009). Therefore,
understanding the mechanisms of drug resistance in pancreatic
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the development of novel therapeutic approaches or improve
current therapy.
Chemokine signalling has long been implicated in cancer
progression and metastasis through autocrine or paracrine
mechanisms (Singh et al, 2007). Importantly, in previous studies,
a chemokine receptor, CXCR4, was shown to be overexpressed in
pancreatic cancer tissues and CSCs (Hermann et al, 2007; Thomas
et al, 2008; Marechal et al, 2009) and has been shown to potentiate
pancreatic cancer growth and invasion (Marchesi et al, 2004; Mori
et al, 2004; Hermann et al, 2007). Here, we investigated another
aspect of this signalling node in protecting pancreatic cancer
cells from chemotherapeutic drug-induced apoptosis. We observed
that all the pancreatic cancer cell lines tested expressed CXCR4,
but low levels of CXCL12. Nonetheless, we observed signifi-
cant protection of pancreatic cancer cells from gemcitabine
toxicity on co-treatment with exogenous CXCL12, indicating a
role for CXCL12–CXCR4 signalling axis in pancreatic cancer
chemoresistance. As CXCL12 is abundantly expressed by stromal
cells (Matsuo et al, 2009), this could be an exemplary example for
the role of tumour microenvironment interaction in modulating
the therapeutic response. To gain an insight into the mechanistic
basis for the protective effects, we examined the activation of
downstream signalling pathways. Consistent with previous reports
(Glodek et al, 2007; Lu et al, 2009; Shen et al, 2010), CXCL12
induced the activation of FAK, Akt, and ERK. In a recent study,
activation of FAK by extracellular matrix–integrin signalling was
shown to promote the chemoresistance of pancreatic cancer cells
(Huanwen et al, 2009). Akt and ERK have also been shown to
promote survival signalling (Middleton et al, 2008), and constitu-
tive or induced activation of ERK and Akt pathways has been
previously associated with chemoresistant behaviour of pancreatic
cancer cells (Yokoi and Fidler, 2004; Zhao et al, 2006). In fact,
FAK-associated chemoresistance of pancreatic cancer cells was
shown to be mediated, in part, by the activation of PI3K/Akt
pathway (Huanwen et al, 2009).
Both Akt and ERK can transduce survival signals directly or
indirectly. In direct course, Akt and ERK have been shown to
phosphorylate BAD, a proapoptotic member of the Bcl-2 family
(Datta et al, 1997; Scheid and Duronio, 1998; Sheridan et al, 2008).
Phosphorylation prevents BAD from binding either Bcl-2 or
Bcl-xL, and thus suppresses apoptosis. In the indirect route,
induction of survival protein expression occurs through the
activation of b-catenin and NF-kB pathways. Activation of ERK
has been shown to promote transactivation of b-catenin by
phosphorylating a-catenin (Ji et al, 2009). Furthermore, Akt can
activate b-catenin by inducing direct phosphorylation or by
inactivating GSK-3b (Monick et al, 2001; Fang et al, 2007; Korkaya
et al, 2009). In other reports, Akt pathway has been shown to
regulate NF-kB, and NF-kB was shown to be essential for
oncogenic transformation by PI3K and Akt (Ozes et al, 1999;
Romashkova and Makarov, 1999; Sizemore et al, 1999; Madrid
et al, 2000). Akt-induced activation of NF-kB likely occurs through
phosphorylation of IKKa, which then targets the IkB inhibitor
protein and phosphorylates the p65 NF-kB subunit (Ozes et al,
1999; Madrid et al, 2000; Bai et al, 2009). Consistent with these
findings, we also observed enhanced transcriptional activities of
b-catenin and NF-kB responsive promoters and expression of
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Enhanced transcriptional activity of b-catenin and NF-kB has been
shown to induce epithelial to mesenchymal transition (EMT), and
in recent studies, EMT has been associated with drug-resistant
nature of pancreatic cancer cells (Li et al, 2009; Wang et al, 2009).
In fact, relative drug-resistant nature of pancreatic cancer cells has
been correlated with the mesenchymal phenotype (Shah et al,
2007). Other studies have shown that the underlying resistance to
apoptosis is, in part, due to constitutive activation of NF-kBi n
pancreatic cancer (Harikumar et al, 2010; Wang et al, 2010). Our
results also indicate that the CXCL12-induced gemcitabine
resistance in pancreatic cancer cells might, in part, also be due
to the activation of NF-kB and induction of downstream survival
proteins (Bcl-2, Bcl-xL, survivin, and so on).
The use of small-molecule inhibitors represents an attractive
targeted therapeutic approach. Previously, we showed that
targeting of chemokine receptors, CXCR1 and CXCR2, in
malignant melanoma by small-molecule antagonists led to reduced
tumour growth, invasion, and angiogenesis (Singh et al, 2009).
Here, we utilised AMD3100, a specific antagonist of CXCR4, to
target CXCR4 activation in response to CXCL12 treatment and
demonstrate its efficacy in abolishing the chemoprotective effect of
CXCL12–CXCR4 signalling axis. The therapeutic potential of
AMD3100 has been studied largely in fighting HIV infection
(De, 2003), although there are also some recent reports that
highlight its therapeutic use in cancer (Yasumoto et al, 2006; Azab
et al, 2009). In the same line, our data also indicate that AMD3100
might be useful in targeting the CXCL12–CXCR4 signalling axis in
pancreatic cancer. Pharmacokinetics and safety of AMD3100 has
been studied in human volunteers after intravenous injection
and shown to have minimal side effects (Hendrix et al, 2000).
Therefore, AMD3100 can serve as a novel therapeutics for
pancreatic cancer alone or in combination with cytotoxic drug.
In conclusion, our findings provide additional support for the
pathological role of CXCL12–CXCR4 signalling in pancreatic
cancer, and demonstrate, for the first time, a role for this axis in
drug resistance. Our data show that the induced chemo-
resistance is partly mediated by the activation of Akt and ERK
signalling pathways and a small-molecule antagonist against
CXCR4 can effectively abrogate the survival signals and resensitise
the pancreatic cancer cells to gemcitabine cytotoxicity. Therefore,
future clinical trials in pancreatic cancer might benefit from
targeting of this signalling axis alone or in combination with
chemotherapy.
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